Christine Ryan - Gabather VP Operations
| GABA Stock | SEK 0.56 0.01 1.75% |
Insider
Christine Ryan is VP Operations of Gabather AB
| Phone | 46 7 02 31 22 92 |
| Web | https://www.gabather.com |
Gabather Management Efficiency
The company has return on total asset (ROA) of (0.4827) % which means that it has lost $0.4827 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (1.1871) %, meaning that it generated substantial loss on money invested by shareholders. Gabather's management efficiency ratios could be used to measure how well Gabather manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | INSIDER Age | ||
| Kjell Sjstrm | Cantargia AB | N/A | |
| Jesper Wiklund | Klaria Pharma Holding | 54 | |
| Adnan Deronic | Cantargia AB | N/A | |
| Susanne Lagerlund | Cantargia AB | N/A | |
| Hans MD | Klaria Pharma Holding | 65 | |
| Mathias Skalmstad | Sprint Bioscience AB | N/A | |
| Henrik Nittmar | Corline Biomedical AB | 57 | |
| Prof MBA | Sprint Bioscience AB | 64 | |
| Nina Valkama | Cantargia AB | N/A | |
| Kia Bengtsson | Lidds AB | 54 | |
| Peter Madsen | Cantargia AB | N/A | |
| Matthew Lindon | Lidds AB | 50 | |
| Johan MD | Lidds AB | 69 | |
| Marc Willuhn | Klaria Pharma Holding | 54 | |
| Thoas MD | Cantargia AB | 61 | |
| Pr Tufveson | Corline Biomedical AB | N/A | |
| Dominique Tersago | Cantargia AB | 61 | |
| Jenni Bjornulfson | Lidds AB | 52 | |
| Fredrik Hubinette | Klaria Pharma Holding | 54 | |
| Marcuss | Cantargia AB | N/A | |
| Anders Mansson | Lidds AB | 56 | |
Management Performance
| Return On Equity | -1.19 | |||
| Return On Asset | -0.48 |
Gabather AB Leadership Team
Elected by the shareholders, the Gabather's board of directors comprises two types of representatives: Gabather inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Gabather. The board's role is to monitor Gabather's management team and ensure that shareholders' interests are well served. Gabather's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Gabather's outside directors are responsible for providing unbiased perspectives on the board's policies.
| MichaelRobin Witt, Chief Officer | ||
| Christine Ryan, VP Operations |
Gabather Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Gabather a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -1.19 | |||
| Return On Asset | -0.48 | |||
| Current Valuation | 57.55 M | |||
| Shares Outstanding | 13.63 M | |||
| Shares Owned By Insiders | 27.75 % | |||
| Price To Book | 11.09 X | |||
| EBITDA | (16.99 M) | |||
| Net Income | (17 M) | |||
| Cash And Equivalents | 14.85 M | |||
| Book Value Per Share | 0.25 X |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Gabather Stock Analysis
When running Gabather's price analysis, check to measure Gabather's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Gabather is operating at the current time. Most of Gabather's value examination focuses on studying past and present price action to predict the probability of Gabather's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Gabather's price. Additionally, you may evaluate how the addition of Gabather to your portfolios can decrease your overall portfolio volatility.